RNS Number : 3927R
Shield Therapeutics PLC
05 March 2021

Shield Therapeutics plc
("Shield Therapeutics" or the "Company")

PDMR Transaction Notification

London, UK, 05 March 2021: Shield Therapeutics plc (LSE:STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru®, announces that Hans Peter Hasler, Non-Executive Chairman, acquired 200,000 Ordinary Shares in the Company on 05 March 2021 at an average price of 0.375 pence per share. Following the transaction, Mr Hasler has a beneficial interest in 500,000 shares.

The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

1.	**Details of the person discharging managerial responsibilities / person closely associated**	
a.	Name	Hans Peter Hasler
2.	**Reason for the notification**	
a.	Position/status	Non-Executive Chairman
b.	Initial notification /Amendment	Initial
3.	**Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**	
a.	Name	Shield Therapeutics plc
b.	LEI	213800G74QWY15FC3W71
4.	**Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**	
a.	Description of the Financial instrument, type of instrument Identification code	Ordinary shares of 1.5p each in the capital of the Company ISIN of Ordinary Shares: GB00BYV81293
b.	Nature of the transaction	Acquisition of Ordinary Shares
c.	Price(s) and volume(s)	Price(s) / Volume(s)

		£0.375	200,000
d.	Aggregated information · *Aggregated volume* · *Price*	200,000 £75,000	
e.	Date of the transaction	2021-03-05	
f.	Place of the transaction	London Stock Exchange, AIM Market	

For further information, please contact:

Shield Therapeutics plc +44 (0) 191 511 8500
Tim Watts (CEO)

Peel Hunt LLP - **Nominated Adviser, Joint Broker and Bookrunner** +44 (0) 20 7148 8900
James Steel / Dr Christopher Golden

finnCap Ltd - Joint Broker and Bookrunner +44 (0) 20 7220 0500
Geoff Nash / Matthew Radley / Alice Lane

Walbrook PR - Financial PR & IR Adviser +44 (0) 20 7933 8780
Paul McManus / Lianne Cawthorne or shield@walbrookpr.com

About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru® /Accrufer® (ferric maltol)®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Shield is quoted on AIM (STX). For more information about Shield, please see www.shieldtherapeutics.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as

part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHUPUUAWUPGGQA